Broadcom vs American Express: Which Is Best?
Chip giant Broadcom Inc. (NASDAQ:AVGO) and card company American Express…
Sell
2
NUVL Quote, Financials, Valuation and Earnings
Last price:
$78.27
Seasonality move
:
-10.89%
Day range:
$76.67 - $78.51
52-week range:
$61.80 - $113.51
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.96x
Volume:
829.2K
Avg. volume:
427.4K
1-year change:
6.37%
Market cap:
$5.6B
Revenue:
--
EPS (TTM):
-$3.47
Analysts' Opinion
-
Consensus RatingNuvalent has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $115.08, Nuvalent has an estimated upside of 47.01% from its current price of $78.28.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $100.00 representing -27.75% downside risk from its current price of $78.28.
Fair Value
-
According to the consensus of 9 analysts, Nuvalent has 47.01% upside to fair value with a price target of $115.08 per share.
NUVL vs. S&P 500
-
Over the past 5 trading days, Nuvalent has underperformed the S&P 500 by -4.17% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Nuvalent does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nuvalent has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Nuvalent reported revenues of --.
Earnings Growth
-
Nuvalent has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Nuvalent reported earnings per share of -$1.28.
Enterprise value:
4.4B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-28.67x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$74.2M | -$132.4M | -$240.5M | -$38.8M | -$76.3M | |
| EBITDA | -$74.2M | -$132.4M | -$240.5M | -$38.8M | -$76.3M | |
| Diluted EPS | -$1.51 | -$2.03 | -$3.47 | -$0.59 | -$1.28 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $305.1M | $245.2M | $419.8M | $1.2B | |
| Total Assets | -- | $308M | $249.6M | $425.1M | $1.2B | |
| Current Liabilities | -- | $6.8M | $13M | $29.1M | $51.1M | |
| Total Liabilities | -- | $6.8M | $13M | $29.1M | $67.7M | |
| Total Equity | -- | $301.1M | $236.6M | $396M | $1.1B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$60.1M | -$87.3M | -$153.3M | -$23M | -$45.8M | |
| Cash From Investing | -$108.7M | -$152.7M | -$459.7M | $38.4M | -$212.9M | |
| Cash From Financing | -$701K | $252.1M | $893.8M | $2.1M | $550.3M | |
| Free Cash Flow | -$60.1M | -$87.3M | -$153.3M | -$23M | -$45.8M | |
NUVL
Sector
Market Cap
$5.6B
$47.7M
Price % of 52-Week High
68.96%
46.05%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
6.37%
-33.33%
Beta (5-Year)
--
0.760
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$81.73
200-day SMA
Sell
Level
$82.32
Bollinger Bands (100)
Sell
Level
82 - 100.76
Chaikin Money Flow
Buy
Level
7.6M
20-day SMA
Sell
Level
$87.19
Relative Strength Index (RSI14)
Sell
Level
24.92
ADX Line
Sell
Level
21.16
Williams %R
Buy
Level
-91.8481
50-day SMA
Sell
Level
$90.64
MACD (12, 26)
Sell
Level
-3.69
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Neutral
Level
5.9M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company’s operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Stock Forecast FAQ
In the current month, NUVL has received 8 Buy ratings 1 Hold ratings, and 0 Sell ratings. The NUVL average analyst price target in the past 3 months is $115.08.
-
Where Will Nuvalent Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nuvalent share price will rise to $115.08 per share over the next 12 months.
-
What Do Analysts Say About Nuvalent?
Analysts are divided on their view about Nuvalent share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nuvalent is a Sell and believe this share price will drop from its current level to $100.00.
-
What Is Nuvalent's Price Target?
The price target for Nuvalent over the next 1-year time period is forecast to be $115.08 according to 9 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is NUVL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nuvalent is a Buy. 8 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NUVL?
You can purchase shares of Nuvalent via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nuvalent shares.
-
What Is The Nuvalent Share Price Today?
Nuvalent was last trading at $78.27 per share. This represents the most recent stock quote for Nuvalent. Yesterday, Nuvalent closed at $78.28 per share.
-
How To Buy Nuvalent Stock Online?
In order to purchase Nuvalent stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Adobe Stock Dropping?
Why is Adobe stock dropping? A combination of underwhelming fiscal…
Why Is 3M Stock Going Up?
After a decade-long slump in new product introductions, the leading…
Stock Ideas
Buy
58
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 41x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
77
FTAI alert for Jan 2
FTAI Aviation [FTAI] is up 2.67% over the past day.
Buy
56
QMCO alert for Jan 2
Quantum [QMCO] is up 5.32% over the past day.
Buy
60
ARQQ alert for Jan 2
Arqit Quantum [ARQQ] is down 0.36% over the past day.
